Canada

ImStar Therapeutics is a private biotechnology company developing new therapeutic approaches to treat patients with neurodegenerative diseases. The lead drug candidate, IMS-088, is a disease-modifying novel compound for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) that acts via rescue of TAR DNA-binding protein 43 (TDP-43) proteinopathy associated with these devastating neurodegenerative diseases. ImStar is also developing mAb therapeutics directed at TDP-43.

Presenter: Daniel Wattier, CEO, ImStar Therapeutics